APAC Uterine Cancer Drug Market - Industry Trends and Forecast to 2031

Description

List of Tables

The Asia-pacific uterine cancer drugs market is expected to reach USD 958,896.20 million by 2030 from USD 550,332.54 million in 2022, growing at a CAGR of 7.7% during the forecast period of 2023 to 2030.

Market Segmentation

Asia-pacific Uterine Cancer Drugs Market, By Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generic and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, and rest of Asia-Pacific) - Industry Trends and Forecast to 2030.

Overview of Asia-pacific Uterine Cancer Drugs Market Dynamics

Driver
Rising incidence of uterine cancer worldwide
Restraint
High cost of uterine cancer treatment
Opportunity
Advancement in genomic profiling and biomarker discovery

Market Players

Some of the major market players operating in the Asia-pacific uterine cancer drugs market are listed below:

Baxter
Eli Lilly and Company
Hikma Pharmaceuticals PLC
Sun Pharmaceutical Industries Ltd.
Fresenius SE & Co. KGaA
Viatris Inc.
Sanofi
Teva Pharmaceuticals USA, Inc.
Amneal Pharmaceuticals LLC
Merck & Co., Inc.
GSK plc.
Eisai Co., Ltd.
Pfizer Inc.
Getwell Oncology

1 INTRODUCTION 24

1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF THE ASIA - PACIFIC UTERINE CANCER DRUGS MARKET 24
1.4 LIMITATIONS 26
1.5 MARKETS COVERED 26

2 MARKET SEGMENTATION 29

2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 CURRENCY AND PRICING 31
2.5 DBMR TRIPOD DATA VALIDATION MODEL 32
2.6 MULTIVARIATE MODELLING 35
2.7 CANCER TYPE LIFELINE CURVE 35
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.9 DBMR MARKET POSITION GRID 37
2.10 MARKET END USER COVERAGE GRID 38
2.11 VENDOR SHARE ANALYSIS 39
2.12 SECONDARY SOURCES 40
2.13 ASSUMPTIONS 40

3 EXECUTIVE SUMMARY 41

4 PREMIUM INSIGHTS 44

4.1 PESTEL'S MODEL 45
4.2 PORTER'S 5 FORCES 46
4.3 EPIDEMIOLOGY 47

5 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, REGULATORY FRAMEWORK 48

5.1 OVERVIEW 48
5.2 REGULATION IN THE U.S. 49
5.3 REGULATION IN CANADA 49
5.4 REGULATION IN EUROPE 49
5.5 REGULATION IN CHINA 49
5.6 REGULATION IN JAPAN 49
5.7 REGULATION IN AUSTRALIA 50
5.8 REGULATION IN INDIA 50
5.9 REGULATION IN BRAZIL 50
5.10 REGULATION IN SOUTH AFRICA 50

6 MARKET OVERVIEW 51

6.1 DRIVERS 53
- 6.1.1 RISING INCIDENCE OF UTERINE CANCER WORLDWIDE 53
- 6.1.2 GROWING ADVANCEMENTS IN TARGETED THERAPY FOR UTERINE CANCER 54
- 6.1.3 RISING AWARENESS OF UTERINE CANCER 55
- 6.1.4 RISING COLLABORATIONS AND PARTNERSHIPS AMONG LEADING PLAYERS 56
6.2 RESTRAINTS 57
- 6.2.1 HIGH COST OF UTERINE CANCER TREATMENT 57
- 6.2.2 SIDE EFFECTS AND TOXICITY ASSOCIATED WITH CANCER DRUGS 58
6.3 OPPORTUNITIES 59
- 6.3.1 ADVANCEMENTS IN GENOMIC PROFILING AND BIOMARKER DISCOVERY 59
- 6.3.2 GROWING R&D ACTIVITIES FOR UTERINE CANCER TREATMENT 60
6.4 CHALLENGES 61
- 6.4.1 REGULATORY HURDLES IN THE UTERINE CANCER DRUGS MARKET 61
- 6.4.2 DRUG RESISTANCE IN THE TREATMENT OF UTERINE CANCER 62

7 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY CANCER TYPE 64

7.1 OVERVIEW 65
7.2 ENDOMETRIAL CANCER 68
- 7.2.1 UTERINE CARCINOSARCOMA 69
- 7.2.2 SEROUS ADENOSARCOMA 69
- 7.2.3 ADENOSQUAMOUS CARCINOMA 69
- 7.2.4 OTHER 69
7.3 UTERINE SARCOMA 70
- 7.3.1 UTERINE LEIOMYOSARCOMA 70
- 7.3.2 ENDOMETRIAL STROMAL SARCOMAS 70
- 7.3.3 UNDIFFERENTIATED SARCOMA 71

8 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE 72

8.1 OVERVIEW 73
8.2 CHEMOTHERAPY 76
- 8.2.1 PACLITAXEL 77
- 8.2.2 CARBOPLATIN 77
- 8.2.3 CISPLATIN 77
- 8.2.4 DOXORUBICIN 77
- 8.2.5 DOCETAXEL 77
- 8.2.6 OTHERS 77
8.3 IMMUNOTHERAPY 78
8.4 HORMONE THERAPY 78
- 8.4.1 PROGESTINS 79
  - 8.4.1.1 MEDROXYPROGESTERONE ACETATE 79
  - 8.4.1.2 OTHERS 79
- 8.4.2 AROMATASE INHIBITORS 80
  - 8.4.2.1 LETRAZOLE 80
  - 8.4.2.2 ANASTRAZOLE 80
  - 8.4.2.3 EXEMESTANE 80
- 8.4.3 LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS 81
  - 8.4.3.1 GOSERELIN 81
  - 8.4.3.2 LEUPROLIDE 81
- 8.4.4 OTHERS 81
8.5 TARGETED THERAPY 82
- 8.5.1 LENVATINAB 82
- 8.5.2 BEVACIZUMAB 82
- 8.5.3 MTOR INHIBITORS 82
  - 8.5.3.1 EVEROLIMUS 83
  - 8.5.3.2 TEMSIROLIMUS 83
8.6 OTHERS 83

9 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY DRUG TYPE 84

9.1 OVERVIEW 85
9.2 GENERICS 88
9.3 BRANDED 88
- 9.3.1 KEYTRUDA 89
- 9.3.2 LENVIMA 89
- 9.3.3 PROVERA 90
- 9.3.4 TEMODAR 90
- 9.3.5 JEMPERLI 90
- 9.3.6 OTHERS 90

10 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY AGE GROUP 91

10.1 OVERVIEW 92
10.2 GERIATRIC 95
10.3 ADULTS 95

11 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION 96

11.1 OVERVIEW 97
11.2 PARENTERAL 100
11.3 ORAL 100

12 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY END USER 101

12.1 OVERVIEW 102
12.2 HOSPITALS 105
- 12.2.1 PRIVATE 105
- 12.2.2 PUBLIC 105
12.3 CANCER CENTERS 106
12.4 SPECIALTY CLINICS 106
12.5 OTHERS 107

13 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL 108

13.1 OVERVIEW 109
13.2 DIRECT TENDER 112
13.3 RETAIL SALES 112
- 13.3.1 HOSPITAL PHARMACY 113
- 13.3.2 RETAIL PHARMACY 113
- 13.3.3 ONLINE PHARMACY 113
13.4 OTHERS 114

14 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY REGION 115

14.1 ASIA-PACIFIC 118
- 14.1.1 CHINA 124
- 14.1.2 JAPAN 129
- 14.1.3 INDIA 134
- 14.1.4 AUSTRALIA 139
- 14.1.5 SOUTH KOREA 144
- 14.1.6 NEW ZEALAND 149
- 14.1.7 SINGAPORE 154
- 14.1.8 THAILAND 159
- 14.1.9 MALAYSIA 164
- 14.1.10 INDONESIA 169
- 14.1.11 PHILIPPINES 174
- 14.1.12 REST OF ASIA-PACIFIC 179

15 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, COMPANY LANDSCAPE 180

15.1 COMPANY SHARE ANALYSIS: ASIA - PACIFIC 180

16 SWOT ANALYSIS 181

17 COMPANY PROFILES 182

17.1 MERCK & CO., INC. 182
- 17.1.1 COMPANY SNAPSHOT 182
- 17.1.2 REVENUE ANALYSIS 182
- 17.1.3 COMPANY SHARE ANALYSIS 183
- 17.1.4 PRODUCT PORTFOLIO 183
- 17.1.5 RECENT DEVELOPMENT 184
17.2 EISAI CO., LTD. 185
- 17.2.1 COMPANY SNAPSHOT 185
- 17.2.2 REVENUE ANALYSIS 185
- 17.2.3 COMPANY SHARE ANALYSIS 186
- 17.2.4 PRODUCT PORTFOLIO 186
- 17.2.5 RECENT DEVELOPMENT 186
- 17.2.6 RECENT DEVELOPMENT 187
17.3 SANOFI 188
- 17.3.1 COMPANY SNAPSHOT 188
- 17.3.2 REVENUE ANALYSIS 188
- 17.3.3 COMPANY SHARE ANALYSIS 189
- 17.3.4 PRODUCT PORTFOLIO 189
- 17.3.5 RECENT DEVELOPMENT 190
17.4 PFIZER INC. 191
- 17.4.1 COMPANY SNAPSHOT 191
- 17.4.2 REVENUE ANALYSIS 191
- 17.4.3 COMPANY SHARE ANALYSIS 192
- 17.4.4 PRODUCT PORTFOLIO 192
- 17.4.5 RECENT DEVELOPMENT 194
17.5 TEVA PHARMACEUTICALS USA, INC. 195
- 17.5.1 COMPANY SNAPSHOT 195
- 17.5.2 REVENUE ANALYSIS 195
- 17.5.3 PRODUCT PORTFOLIO 196
- 17.5.4 RECENT DEVELOPMENT 196
17.6 ACCORD HEALTHCARE US. 197
- 17.6.1 COMPANY SNAPSHOT 197
- 17.6.2 PRODUCT PORTFOLIO 197
- 17.6.3 RECENT DEVELOPMENT 197
17.7 AMNEAL PHARMACEUTICALS LLC 198
- 17.7.1 COMPANY SNAPSHOT 198
- 17.7.2 REVENUE ANALYSIS 198
- 17.7.3 PRODUCT PORTFOLIO 199
- 17.7.4 RECENT DEVELOPMENT 199
17.8 BAXTER 200
- 17.8.1 COMPANY SNAPSHOT 200
- 17.8.2 REVENUE ANALYSIS 200
- 17.8.3 COMPANY SHARE ANALYSIS 201
- 17.8.4 PRODUCT PORTFOLIO 201
- 17.8.5 RECENT DEVELOPMENT 201
17.9 ELI LILLY AND COMPANY 202
- 17.9.1 COMPANY SNAPSHOT 202
- 17.9.2 REVENUE ANALYSIS 203
- 17.9.3 PRODUCT PORTFOLIO 203
- 17.9.4 RECENT DEVELOPMENT 204
17.10 GETWELL ONCOLOGY 205
- 17.10.1 COMPANY SNAPSHOT 205
- 17.10.2 PRODUCT PORTFOLIO 205
- 17.10.3 RECENT DEVELOPMENT 208
17.11 GSK PLC. 209
- 17.11.1 COMPANY SNAPSHOT 209
- 17.11.2 REVENUE ANALYSIS 209
- 17.11.3 PRODUCT PORTFOLIO 210
- 17.11.4 RECENT DEVELOPMENT 210
17.12 HIKMA PHARMACEUTICALS PLC 211
- 17.12.1 COMPANY SNAPSHOT 211
- 17.12.2 REVENUE ANALYSIS 211
- 17.12.3 PRODUCT PORTFOLIO 212
- 17.12.4 RECENT DEVELOPMENT 212
17.13 SUN PHARMACEUTICAL INDUSTRIES LTD. 213
- 17.13.1 COMPANY SNAPSHOT 213
- 17.13.2 REVENUE ANALYSIS 213
- 17.13.3 PRODUCT PORTFOLIO 214
- 17.13.4 RECENT DEVELOPMENT 214
17.14 VIATRIS INC. 215
- 17.14.1 COMPANY SNAPSHOT 215
- 17.14.2 REVENUE ANALYSIS 215
- 17.14.3 PRODUCT PORTFOLIO 216
- 17.14.4 RECENT DEVELOPMENT 216
17.15 VIRTUS 217
- 17.15.1 COMPANY SNAPSHOT 217
- 17.15.2 PRODUCT PORTFOLIO 217
- 17.15.3 RECENT DEVELOPMENT 217

18 QUESTIONNAIRE 218

19 RELATED REPORTS 222

LIST OF TABLES

TABLE 1 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2022-2030 (USD THOUSAND) 67
TABLE 2 ASIA - PACIFIC ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
TABLE 3 ASIA - PACIFIC ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 69
TABLE 4 ASIA - PACIFIC UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 70
TABLE 5 ASIA - PACIFIC UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 70
TABLE 6 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 75
TABLE 7 ASIA - PACIFIC CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
TABLE 8 ASIA - PACIFIC CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 76
TABLE 9 ASIA - PACIFIC IMMUNOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 78
TABLE 10 ASIA - PACIFIC HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 78
TABLE 11 ASIA - PACIFIC HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 79
TABLE 12 ASIA - PACIFIC PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 79
TABLE 13 ASIA - PACIFIC AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 80
TABLE 14 ASIA - PACIFIC LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 81
TABLE 15 ASIA - PACIFIC TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
TABLE 16 ASIA - PACIFIC TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 82
TABLE 17 ASIA - PACIFIC MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 83
TABLE 18 ASIA - PACIFIC OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 83
TABLE 19 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 87
TABLE 20 ASIA - PACIFIC GENERICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
TABLE 21 ASIA - PACIFIC BRANDED IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
TABLE 22 ASIA - PACIFIC BRANDED IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 89
TABLE 23 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2022-2030 (USD THOUSAND) 94
TABLE 24 ASIA - PACIFIC GERIATRIC IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
TABLE 25 ASIA - PACIFIC ADULTS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
TABLE 26 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 99
TABLE 27 ASIA - PACIFIC PARENTERAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 100
TABLE 28 ASIA - PACIFIC ORAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 100
TABLE 29 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY END USER, 2022-2030 (USD THOUSAND) 104
TABLE 30 ASIA - PACIFIC HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 105
TABLE 31 ASIA - PACIFIC HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 105
TABLE 32 ASIA - PACIFIC CANCER CENTERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 106
TABLE 33 ASIA - PACIFIC SPECIALTY CLINICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 106
TABLE 34 ASIA - PACIFIC OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 107
TABLE 35 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD THOUSAND) 111
TABLE 36 ASIA - PACIFIC DIRECT TENDER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 112
TABLE 37 ASIA - PACIFIC RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 112
TABLE 38 ASIA - PACIFIC RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 113
TABLE 39 ASIA - PACIFIC OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 114
TABLE 40 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 118
TABLE 41 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 118
TABLE 42 ASIA-PACIFIC ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 43 ASIA-PACIFIC UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 44 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 45 ASIA-PACIFIC CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 120
TABLE 46 ASIA-PACIFIC HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 47 ASIA-PACIFIC PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 120
TABLE 48 ASIA-PACIFIC AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 120
TABLE 49 ASIA-PACIFIC LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 121
TABLE 50 ASIA-PACIFIC TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 121
TABLE 51 ASIA-PACIFIC MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 121
TABLE 52 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 121
TABLE 53 ASIA-PACIFIC BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 121
TABLE 54 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 122
TABLE 55 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 122
TABLE 56 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 122
TABLE 57 ASIA-PACIFIC HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 58 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 122
TABLE 59 ASIA-PACIFIC RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 123
TABLE 60 CHINA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 61 CHINA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 62 CHINA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 63 CHINA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 64 CHINA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 125
TABLE 65 CHINA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 66 CHINA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 125
TABLE 67 CHINA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 125
TABLE 68 CHINA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 126
TABLE 69 CHINA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 70 CHINA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 126
TABLE 71 CHINA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 72 CHINA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 126
TABLE 73 CHINA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 127
TABLE 74 CHINA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 127
TABLE 75 CHINA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 127
TABLE 76 CHINA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 77 CHINA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 127
TABLE 78 CHINA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 128
TABLE 79 JAPAN UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 80 JAPAN ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 81 JAPAN UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 82 JAPAN UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 83 JAPAN CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 130
TABLE 84 JAPAN HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 85 JAPAN PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 130
TABLE 86 JAPAN AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 131
TABLE 87 JAPAN LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 131
TABLE 88 JAPAN TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 89 JAPAN MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 131
TABLE 90 JAPAN UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 91 JAPAN BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 132
TABLE 92 JAPAN UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 132
TABLE 93 JAPAN UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 132
TABLE 94 JAPAN UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 132
TABLE 95 JAPAN HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 132
TABLE 96 JAPAN UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 133
TABLE 97 JAPAN RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
TABLE 98 INDIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 99 INDIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 100 INDIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 101 INDIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 102 INDIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 135
TABLE 103 INDIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 104 INDIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 135
TABLE 105 INDIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 135
TABLE 106 INDIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 136
TABLE 107 INDIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 108 INDIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 136
TABLE 109 INDIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 110 INDIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 136
TABLE 111 INDIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 137
TABLE 112 INDIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 137
TABLE 113 INDIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 137
TABLE 114 INDIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 137
TABLE 115 INDIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 137
TABLE 116 INDIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 138
TABLE 117 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 118 AUSTRALIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 119 AUSTRALIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 120 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 121 AUSTRALIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 140
TABLE 122 AUSTRALIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 123 AUSTRALIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 140
TABLE 124 AUSTRALIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 141
TABLE 125 AUSTRALIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 141
TABLE 126 AUSTRALIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 141
TABLE 127 AUSTRALIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 141
TABLE 128 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 141
TABLE 129 AUSTRALIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 142
TABLE 130 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 142
TABLE 131 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 142
TABLE 132 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 142
TABLE 133 AUSTRALIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 134 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 143
TABLE 135 AUSTRALIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 136 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 144
TABLE 137 SOUTH KOREA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 144
TABLE 138 SOUTH KOREA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 144
TABLE 139 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 145
TABLE 140 SOUTH KOREA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 145
TABLE 141 SOUTH KOREA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 145
TABLE 142 SOUTH KOREA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 146
TABLE 143 SOUTH KOREA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 146
TABLE 144 SOUTH KOREA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 146
TABLE 145 SOUTH KOREA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 146 SOUTH KOREA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 146
TABLE 147 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 147
TABLE 148 SOUTH KOREA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 147
TABLE 149 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 147
TABLE 150 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 147
TABLE 151 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 148
TABLE 152 SOUTH KOREA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 148
TABLE 153 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 148
TABLE 154 SOUTH KOREA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 148
TABLE 155 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 149
TABLE 156 NEW ZEALAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 149
TABLE 157 NEW ZEALAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 149
TABLE 158 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 159 NEW ZEALAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 150
TABLE 160 NEW ZEALAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 161 NEW ZEALAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 151
TABLE 162 NEW ZEALAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 151
TABLE 163 NEW ZEALAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 151
TABLE 164 NEW ZEALAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 165 NEW ZEALAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 151
TABLE 166 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 152
TABLE 167 NEW ZEALAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 152
TABLE 168 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 152
TABLE 169 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 152
TABLE 170 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 153
TABLE 171 NEW ZEALAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 153
TABLE 172 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 153
TABLE 173 NEW ZEALAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 153
TABLE 174 SINGAPORE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 175 SINGAPORE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 176 SINGAPORE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 177 SINGAPORE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 178 SINGAPORE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 155
TABLE 179 SINGAPORE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 180 SINGAPORE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 155
TABLE 181 SINGAPORE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 156
TABLE 182 SINGAPORE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 156
TABLE 183 SINGAPORE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 156
TABLE 184 SINGAPORE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 156
TABLE 185 SINGAPORE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 156
TABLE 186 SINGAPORE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 157
TABLE 187 SINGAPORE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 157
TABLE 188 SINGAPORE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 157
TABLE 189 SINGAPORE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 157
TABLE 190 SINGAPORE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 157
TABLE 191 SINGAPORE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 158
TABLE 192 SINGAPORE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 193 THAILAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 159
TABLE 194 THAILAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 159
TABLE 195 THAILAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 159
TABLE 196 THAILAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 160
TABLE 197 THAILAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 160
TABLE 198 THAILAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 160
TABLE 199 THAILAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 160
TABLE 200 THAILAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 161
TABLE 201 THAILAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 161
TABLE 202 THAILAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 161
TABLE 203 THAILAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 161
TABLE 204 THAILAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 161
TABLE 205 THAILAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 162
TABLE 206 THAILAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 162
TABLE 207 THAILAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 162
TABLE 208 THAILAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 162
TABLE 209 THAILAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 162
TABLE 210 THAILAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 163
TABLE 211 THAILAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 163
TABLE 212 MALAYSIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 164
TABLE 213 MALAYSIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 164
TABLE 214 MALAYSIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 164
TABLE 215 MALAYSIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 165
TABLE 216 MALAYSIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 165
TABLE 217 MALAYSIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 165
TABLE 218 MALAYSIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 166
TABLE 219 MALAYSIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 166
TABLE 220 MALAYSIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 166
TABLE 221 MALAYSIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 166
TABLE 222 MALAYSIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 166
TABLE 223 MALAYSIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 167
TABLE 224 MALAYSIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 167
TABLE 225 MALAYSIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 167
TABLE 226 MALAYSIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 167
TABLE 227 MALAYSIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 167
TABLE 228 MALAYSIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 168
TABLE 229 MALAYSIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 168
TABLE 230 MALAYSIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 168
TABLE 231 INDONESIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 169
TABLE 232 INDONESIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 169
TABLE 233 INDONESIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 169
TABLE 234 INDONESIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 170
TABLE 235 INDONESIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 170
TABLE 236 INDONESIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 170
TABLE 237 INDONESIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 171
TABLE 238 INDONESIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 171
TABLE 239 INDONESIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 171
TABLE 240 INDONESIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 171
TABLE 241 INDONESIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 171
TABLE 242 INDONESIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 172
TABLE 243 INDONESIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 172
TABLE 244 INDONESIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 172
TABLE 245 INDONESIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 172
TABLE 246 INDONESIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 172
TABLE 247 INDONESIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 173
TABLE 248 INDONESIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 173
TABLE 249 INDONESIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 173
TABLE 250 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 174

TABLE 251 PHILIPPINES ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 174
TABLE 252 PHILIPPINES UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 174
TABLE 253 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 175
TABLE 254 PHILIPPINES CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 175
TABLE 255 PHILIPPINES HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 175
TABLE 256 PHILIPPINES PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 176
TABLE 257 PHILIPPINES AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 176
TABLE 258 PHILIPPINES LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 176
TABLE 259 PHILIPPINES TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 176
TABLE 260 PHILIPPINES MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 176
TABLE 261 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 177
TABLE 262 PHILIPPINES BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 177
TABLE 263 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 177
TABLE 264 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 177
TABLE 265 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 178
TABLE 266 PHILIPPINES HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 178
TABLE 267 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 178
TABLE 268 PHILIPPINES RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 178
TABLE 269 REST OF ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 179

LIST OF FIGURES

FIGURE 1 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: SEGMENTATION 29
FIGURE 2 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: DATA TRIANGULATION 32
FIGURE 3 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: DROC ANALYSIS 33
FIGURE 4 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET : ASIA - PACIFIC VS REGIONAL MARKET ANALYSIS 34
FIGURE 5 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS 34
FIGURE 6 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS 36
FIGURE 7 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: DBMR MARKET POSITION GRID 37
FIGURE 8 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID 38
FIGURE 9 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: VENDOR SHARE ANALYSIS 39
FIGURE 10 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: SEGMENTATION 43
FIGURE 11 RISING INCIDENCE OF UTERINE CANCER IS EXPECTED TO DRIVE THE GROWTH OF THE ASIA - PACIFIC UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 44
FIGURE 12 ENDOMETRIAL CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA - PACIFIC UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 AND 2030 44
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA - PACIFIC UTERINE CANCER DRUGS MARKET 52
FIGURE 14 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2022 65
FIGURE 15 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD THOUSAND) 66
FIGURE 16 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030) 66
FIGURE 17 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, LIFELINE CURVE 67
FIGURE 18 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2022 73
FIGURE 19 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 74
FIGURE 20 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, CAGR (2023-2030) 74
FIGURE 21 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, LIFELINE CURVE 75
FIGURE 22 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2022 85
FIGURE 23 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND) 86
FIGURE 24 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030) 86
FIGURE 25 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE 87
FIGURE 26 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY TYPE, 2022 92
FIGURE 27 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD THOUSAND) 93
FIGURE 28 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030) 93
FIGURE 29 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE 94
FIGURE 30 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022 97
FIGURE 31 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 98
FIGURE 32 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 98
FIGURE 33 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 99
FIGURE 34 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY END USER, 2022 102
FIGURE 35 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD THOUSAND) 103
FIGURE 36 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030) 103
FIGURE 37 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE 104
FIGURE 38 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022 109
FIGURE 39 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 110
FIGURE 40 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 110
FIGURE 41 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 111
FIGURE 42 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: SNAPSHOT (2022) 116
FIGURE 43 ASIA - PACIFIC UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 180